You are here

Phase III Trial Evaluates New Irinotecan Formulation in Colorectal Cancer

Goal is progression-free survival (Feb. 28)

A pivotal phase III clinical trial is evaluating HA-Irinotecan (Alchemia Limited) for the treatment of metastatic colorectal cancer in a total of 415 patients in Europe and Australia.

HA-Irinotecan is a new formulation of irinotecan that targets the drug to the tumor, thereby enabling irinotecan to be retained at the tumor site for a longer period and allowing more of the drug to be internalized by the cancer cells. In a phase II trial of HA-Irinotecan in metastatic colorectal cancer, the new formulation achieved a statistically significant increase in progression-free survival (PFS) compared with irinotecan (5.2 months vs. 2.4 months, respectively; P = 0.017), with no increase in toxicity.

The FDA has indicated that successful completion of the new phase III trial may be sufficient for the registration of HA-Irinotecan in the U.S.

The double-blind study is being conducted in second- and third-line colorectal cancer patients. The study’s primary objective is to demonstrate an increase in PFS without increasing treatment toxicity.

Source: Alchemia Limited; February 28, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs